I'll research CTVA (Corteva) to build a well-grounded earnings preview. Let me start by gathering recent filings, transcripts, and news.Let me read the most recent earnings materials and the year-ago Q2 for comparison.Let me pull the year-ago Q2 (2025Q2) release for the comparison base, plus recent news and stock price.Let me read the year-ago Q2 2025 earnings release for the comparison base.Let me check for any recent news/filings on the separation between the Q1 call and now.Let me read these two recent 8-Ks for the latest separation and restructuring updates.# Corteva (CTVA) — Q2 2026 Earnings Preview
Corteva heads into Q2 with two stories running in parallel: (1) a business that is executing well and is on the cusp of a full-year guidance revisit, and (2) a corporate breakup — the seed/crop-protection split — that is now moving fast and will dominate the narrative into a September 15 Investor Day. The stock has already priced in a lot of good news: CTVA is up roughly 34% year-to-date (~$67.8 at the start of January to ~$90.5 on July 29) versus a high-single-digit gain for the S&P 500, and trades near 52-week highs. That raises the bar for the print.
Management has a well-telegraphed habit of leaving guidance unchanged in May (Q1) and then updating after Q2 once the North American season is complete. On the Q1 call, CEO Chuck Magro said the first half was "playing out a little better than expected" and that Q1's strength allowed them to "derisk the second half slightly." CFO David Johnson said the first half should now be up more than the ~7% they had originally modeled.
Current FY26 guidance (reaffirmed in May): - Operating EBITDA: $4.0–4.2B (up from FY25's ~$3.75–3.85B guide) - Operating EBITDA margin: 22–23% - Operating EPS: $3.45–3.70 (~7% growth at the midpoint)
Watch for: a raise, particularly to the low end / midpoint. For context, Corteva raised full-year guidance at Q2 last year on 1H strength. Given the Q1 beat (EBITDA +21% YoY) plus favorable tailwinds management flagged — FX (euro then Brazilian real), better royalty trajectory, slightly favorable tariffs, and a lower tax rate — a bump looks like the base-case market expectation. The offsets they'll weigh: a ~$40M 2H oil/inflation headwind and Latin America uncertainty (see below). With the stock near highs, an in-line print with only a modest raise could be a "sell the news" risk.
This is the single most important framing point. Q1 pulled seed volume forward out of Q2 (a timing shift out of Q4'25 and an early-start NA season), so Q2 seed volume comparisons may look optically soft while 1H is what counts. Management explicitly said North America is "a first-half business."
Year-ago comparison bars (2Q25 / 1H25):
| Metric | 2Q25 | 1H25 |
|---|---|---|
| Net sales | $6.46B (+6%) | $10.87B (+3%) |
| Operating EBITDA | $2.16B (+13%) | $3.35B (+14%) |
| Operating EPS | $2.20 (+20%) | $3.33 (+22%) |
| Seed EBITDA | $1.86B (+10%) | $2.71B (+11%) |
| CP EBITDA | $334M (+31%) | $711M (+26%) |
Q1'26 already ran hot (sales +11% reported / +7% organic, Operating EPS $1.50 vs. $1.13). The key question is whether 1H26 EBITDA holds meaningfully above 1H25's $3.35B despite the tough comps.
The structural story is Corteva crossing from royalty-neutral to royalty-positive for the first time in 2026 — a self-help margin lever independent of the ag cycle. Net royalty expense fell another ~$30M in Q1, and there are now 100+ independent licensees for PowerCore Enlist corn and Enlist E3 soybeans. Enlist is tracking to ~65% of US soybean acres and is the #1 soybean technology in the US. Also watch the Brazil soybean licensing ramp (trait penetration expected to cross into double digits this year) and continued price-for-value gains (Seed price/mix +3% in Q1).
CP is where the second-half acceleration is supposed to show up. Management guided CP volumes to step up from low-single-digit gains in 1H toward high-single/double-digit in 2H, driven by Latin America and a back-half-weighted biologicals portfolio (e.g., Utrisha/BlueN). Pricing remains a modest headwind (low-single-digit declines, mostly LatAm competition). Bigger picture: management thinks 2026 is the first year of industry growth in several, with early, tentative signs of a cycle inflection — Chinese AI cost inflation, VAT export controls, and a slight slowdown in China→Brazil exports. Any color quantifying that inflection matters for 2027 setup. New products are pushing ~$2B in revenue.
This is arguably the biggest reason to own or trade the stock here. Timeline and milestones to track: - On track for a Q4 2026 spin. The seed company will be named Vylor (New Corteva keeps crop protection, with new CEO Luke Kissam, who joined June 1). - Vylor filed its first public Form 10 on ~June 26–29 (structured as a reverse spin, with New Corteva as discontinued ops). Post-separation boards for both companies were announced (Magro among directors moving to Vylor). - Capital structure: both entities targeted for investment-grade credit profiles. The Board approved a $1.5B discretionary US pension contribution (~$290M tax benefit) to de-risk New Corteva's balance sheet. Liabilities (incl. pension and legacy EIDP) stay with New Corteva. - Costs: ~$350M one-time separation costs (majority in 2H); net dis-synergies previously ~$100M now trending better (~$50M in the 2026 guide). - Still to come: headquarters decisions, final capital structure, and the September 15 Investor Day, where both companies lay out multi-year financial/strategic plans.
Watch for: any firming of the spin date, when-issued trading timeline, tax-free ruling status, and initial stand-alone leverage/dividend framing. Note separation costs and the $1.5B pension contribution distort GAAP and free cash flow — focus on operating (non-GAAP) metrics and management's underlying ~40–50% FCF conversion target.
On June 12, Corteva raised its Crop Protection Operations Strategy restructuring charges by $100–115M to $750–815M aggregate, tied to the intended closure of its Asturias, Spain production site and revised Pittsburg, California exit estimates (cash outlay $400–443M; program substantially complete by end-2028). Expect questions on incremental cost savings vs. the $300M run-rate productivity target and whether this pressures near-term GAAP results.
Fundamentals are pointed the right way — strong Q1, a royalty-positive inflection, resilient seed pricing, and a 2H CP volume ramp — and the most likely outcome is a full-year guidance raise confirming the "first half better than expected" narrative. But with the stock near highs, the incremental catalyst is less about the Q2 numbers and more about de-risking the second half and advancing the Vylor/New Corteva separation toward the Q4 spin and the September 15 Investor Day. The key things to listen for: (1) magnitude/quality of any guidance raise, (2) LatAm and oil-cost commentary shaping the 2H, and (3) hard details on separation timing, capital structure, and stand-alone financial frameworks.
Note: figures above are drawn from Corteva's Q1 2026 earnings call/release, the Q2 2025 release (the year-ago comparison), recent 8-K disclosures (June 2026 separation and restructuring updates), and market prices through July 29, 2026. Consensus estimates were not available in the sources reviewed; comparisons reference company guidance and prior-year actuals rather than Street consensus.